IMMUTEP Ltd
For the period ended Aug 31, 2026. Filed Sep 2, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Aug 31, 2026 · Filed Sep 2, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · 4. SEGMENT REPORTING
4. SEGMENT REPORTING
Identification of reportable operating segments
Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors, who is identified as the Chief Operating Decision Maker (CODM). The Group operates in one operating segment, Immunotherapy.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.